Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Google Secures Pentagon AI Deal for Classified Projects 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
LONDON, May 02, 2017 -- GW Pharmaceuticals plc (Nasdaq:GWPH), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 9 May, 2017 its second quarter financial results for the period ending 31 March, 2017. GW will also host a conference call the same day at 4:30 p.m. EDT. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
Enquiries: GW Pharmaceuticals plc Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
